Changes in CHA(2)DS(2)-VASc score and risk of ischemic stroke among patients with atrial fibrillation

AIMS: The CHA(2)DS(2)-VASc score is fundamental to stroke risk assessment in atrial fibrillation. However, stroke-related risk factors can be modified later in life. This study aimed to assess the association of changes in CHA(2)DS(2)-VASc score over time (Delta CHA(2)DS(2)-VASc score) with the risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsiartas, Eirinaios, Samaras, Athanasios, Papazoglou, Andreas S., Kartas, Anastasios, Moysidis, Dimitrios V., Gemousakakis, Eleftherios, Kamzolas, Odysseas, Bekiaridou, Alexandra, Doundoulakis, Ioannis, Tzikas, Apostolos, Giannakoulas, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465382/
https://www.ncbi.nlm.nih.gov/pubmed/37311823
http://dx.doi.org/10.1007/s00380-023-02278-1
Descripción
Sumario:AIMS: The CHA(2)DS(2)-VASc score is fundamental to stroke risk assessment in atrial fibrillation. However, stroke-related risk factors can be modified later in life. This study aimed to assess the association of changes in CHA(2)DS(2)-VASc score over time (Delta CHA(2)DS(2)-VASc score) with the risk of ischemic stroke. MATERIALS AND METHODS: This is an observational analysis of 1127 atrial fibrillation patients previously enrolled in the MISOAC-AF trial. After a median 2.6-year follow-up period, baseline and follow-up CHA(2)DS(2)-VASc scores were used to extract the Delta CHA(2)DS(2)-VASc score. The stroke predicting accuracies of the baseline, follow-up, and Delta CHA(2)DS(2)-VASc scores were assessed through regression analyses. RESULTS: The mean baseline, follow-up, and Delta CHA(2)DS(2)-VASc scores were 4.2, 4.8, and 0.6 respectively. Ischemic stroke occurred in 54 (4.4%) patients, of which 83.3% had a Delta CHA(2)DS(2)-VASc score ≥1, contrary to 40.1% of the stroke-free group. The stroke risk per 1-point increase of the CHA(2)DS(2)-VASc score was not significantly associated with the baseline score (aHR=1.14; 95%CI: 0.93-1.41; p=0.201), whereas a significant association was observed with the follow-up (aHR=2.58; 95% CI: 2.07-3.21; p<0.001) and Delta (aHR=4.56; 95%CI: 3.50-5.94; p<0.001) scores. C-index assessment indicated that follow-up and Delta CHA(2)DS(2)-VASc scores were more potent predictors of ischemic stroke compared to baseline. CONCLUSION: In atrial fibrillation patients, changes in CHA(2)DS(2)-VASc score over time were associated with the incidence of stroke. The improved predictability of follow-up and Delta CHA(2)DS(2)-VASc scores indicates that stroke risk is not a static parameter. TRIAL REGISTRATION: This is an observational, post-hoc analysis of the MISOAC-AF randomized controlled trial, registered on ClinicalTrials.gov (identifier: NCT02941978; registered: October 21, 2016). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00380-023-02278-1.

Ejemplares similares